Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;15(Suppl 2):S1116-S1118.
doi: 10.4103/jpbs.jpbs_196_23. Epub 2023 Jul 11.

Comparison of Post-Operative Complications in Oral Cancer Treated with and without Neoadjuvant Chemotherapy

Mridul Kumar Sarma  1 , Ajit K Missong  1 , Moitrayee Sharma  1 , Asim Debnath  1 , Neelakshi Mahanta  2 , Mrinmoy M Choudhury  1
Affiliations

Comparison of Post-Operative Complications in Oral Cancer Treated with and without Neoadjuvant Chemotherapy

Mridul Kumar Sarma et al. J Pharm Bioallied Sci. 2023 Jul.

Abstract

Aim: The aim of the present study was to compare the treatment outcome in oral cancer cases treated with neoadjuvant chemotherapy (NACT) and upfront surgery in localized advance disease.

Materials and methods: A randomized, prospective study was conducted in 20 cases. Patients were divided into two groups. Group A was taken up for upfront surgery and group B was taken up for surgery after two to three cycles of NACT based on patients' response, performance, and compliance.

Results: Neither group showed statistically significant differences in clinical characteristics. In the present study, satisfactory outcomes were seen in nine patients belonging to NACT group and eight patients of non-NACT group had satisfactory outcomes after surgery, which were found to be statistically significant (P = 0.001).

Conclusion: NACT may be considered as a treatment option for oral squamous cell carcinoma patients, particularly those with locally advanced tumors. Further prospective studies are needed to validate these findings in patients.

Keywords: Neoadjuvant chemotherapy; oral cancer; oral squamous cell carcinoma; upfront surgery.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Vishak S, Rangarajan B, Kekatpure VD. Neoadjuvant chemotherapy in oral cancers:Selecting the right patients. Indian J Med Paediatr Oncol. 2015;36:148–53. - PMC - PubMed
    1. Stafford M, Kaczmar J. The neoadjuvant paradigm reinvigorated:A review of pre-surgical immunotherapy in HNSCC. Cancers Head Neck. 2020;5:4. - PMC - PubMed
    1. Su X, Liu Q, Li J, Zhang C, Xue Z, He C, et al. The oncological outcome and influence of neoadjuvant chemotherapy on the surgery in the resectable and locally advanced oral squamous cell carcinoma. Cancer Manag Res. 2019;11:7039–46. - PMC - PubMed
    1. Patil VM, Noronha V, Joshi A, Muddu V, Dhumal S, Bhattacharjee A, et al. Compliance with neoadjuvant chemotherapy in T4 oral cancers:Place, person, socioeconomic status, or assistance. J Glob Oncol. 2015;1:65–72. - PMC - PubMed
    1. Goel A, Singla A, Prabhash K. Neoadjuvant chemotherapy in oral cancer:Current status and future possibilities. Cancer Res Stat Treat. 2020;3:51–9.